Evaluation of Statins Use in Hemodialysis Patients: A Retrospective Analysis of Clinical and Safety Outcomes
<b>Background:</b> Lipid metabolism disturbances are common in end-stage renal disease (ESRD) patients on hemodialysis (HD), leading to dyslipidemia, which is characterized by abnormal plasma lipids and lipoproteins. Although large randomized controlled trials have generally not demonstr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/6/911 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850165404051177472 |
|---|---|
| author | Abdulmalik S. Alotaibi Mohamed A. Albekery Ahmed A. Alanazi Ibrahim S. Alhomoud Khalid A. Alamer Mohammad Shawaqfeh Reem H. Alshammari Fayez Alhejaili Muthana Al Sahlawi Ibrahim Aldossary Hajar Adel Aljuayl Mohammad Alkathiri Shmeylan Alharbi Abdulkareem Albekairy Abdulmalik Alkatheri |
| author_facet | Abdulmalik S. Alotaibi Mohamed A. Albekery Ahmed A. Alanazi Ibrahim S. Alhomoud Khalid A. Alamer Mohammad Shawaqfeh Reem H. Alshammari Fayez Alhejaili Muthana Al Sahlawi Ibrahim Aldossary Hajar Adel Aljuayl Mohammad Alkathiri Shmeylan Alharbi Abdulkareem Albekairy Abdulmalik Alkatheri |
| author_sort | Abdulmalik S. Alotaibi |
| collection | DOAJ |
| description | <b>Background:</b> Lipid metabolism disturbances are common in end-stage renal disease (ESRD) patients on hemodialysis (HD), leading to dyslipidemia, which is characterized by abnormal plasma lipids and lipoproteins. Although large randomized controlled trials have generally not demonstrated a survival benefit associated with statin therapy among patients receiving hemodialysis, limited observational studies have reported potential associations with improved clinical outcomes in this population. <b>Methods</b>: This retrospective cohort study investigated the clinical and safety outcomes of statin use in ESRD patients on HD with documented dyslipidemia over a two-year period from 1 January 2018 to 30 December 2019. The primary endpoints evaluated the clinical outcomes of statins by assessing changes in specific lipid parameters, including low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-C). The secondary endpoints assessed safety by monitoring liver enzymes and creatine kinase (CK) levels. <b>Results</b>: Among 179 participants, diabetes mellitus was present in 134 patients (74.9%), while 168 patients (93.9%) had hypertension. Cardiovascular events occurred in 95 patients (53.1%). Statin therapy was administered to 146 patients (82.0%), with atorvastatin being the most frequently prescribed statin (69.3%). Modest reductions in LDL-C levels were observed in the rosuvastatin and atorvastatin groups, whereas slight increases were noted in the simvastatin and non-statin groups. None of these within-group changes were statistically significant. In the atorvastatin group, LDL-C decreased slightly from 2.058 to 2.003 mmol/L. The rosuvastatin group experienced a more pronounced LDL-C reduction from 2.607 to 2.113 mmol/L. Conversely, the simvastatin group showed an LDL-C increase from 1.550 to 1.901 mmol/L. Among the non-statin group, LDL-C increased from 2.678 to 2.820 mmol/L. Liver enzyme and CK levels fluctuated slightly but remained within normal ranges. <b>Conclusions</b>: This study evaluated statin therapy in hemodialysis patients with dyslipidemia. Although modest reductions in LDL-C levels were observed in the atorvastatin and rosuvastatin groups, statin therapy did not reduce the incidence of atherosclerotic events in hemodialysis patients with dyslipidemia. Additionally, statin use was not associated with any clinically or statistically significant effects. |
| format | Article |
| id | doaj-art-b2f624b6f5b54afdb71b8902ecfa62ac |
| institution | OA Journals |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-b2f624b6f5b54afdb71b8902ecfa62ac2025-08-20T02:21:46ZengMDPI AGPharmaceuticals1424-82472025-06-0118691110.3390/ph18060911Evaluation of Statins Use in Hemodialysis Patients: A Retrospective Analysis of Clinical and Safety OutcomesAbdulmalik S. Alotaibi0Mohamed A. Albekery1Ahmed A. Alanazi2Ibrahim S. Alhomoud3Khalid A. Alamer4Mohammad Shawaqfeh5Reem H. Alshammari6Fayez Alhejaili7Muthana Al Sahlawi8Ibrahim Aldossary9Hajar Adel Aljuayl10Mohammad Alkathiri11Shmeylan Alharbi12Abdulkareem Albekairy13Abdulmalik Alkatheri14Pharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi ArabiaDepartment of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi ArabiaDepartment of Pharmacy Practice, College of Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi ArabiaDepartment of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim 51452, Saudi ArabiaDepartment of Pharmacy Practice, College of Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi ArabiaCollege of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi ArabiaCollege of Pharmacy, Northern Border University, Arar 73213, Saudi ArabiaCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi ArabiaDepartment of Internal Medicine, College of Medicine, King Faisal University, Hofuf 31982, Saudi ArabiaPharmaceutical Care Services, King Abdulaziz Hospital, Ministry of National Guard Health Affairs, Hofuf 31982, Saudi ArabiaDepartment of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi ArabiaCollege of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi ArabiaCollege of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi ArabiaCollege of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi ArabiaCollege of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia<b>Background:</b> Lipid metabolism disturbances are common in end-stage renal disease (ESRD) patients on hemodialysis (HD), leading to dyslipidemia, which is characterized by abnormal plasma lipids and lipoproteins. Although large randomized controlled trials have generally not demonstrated a survival benefit associated with statin therapy among patients receiving hemodialysis, limited observational studies have reported potential associations with improved clinical outcomes in this population. <b>Methods</b>: This retrospective cohort study investigated the clinical and safety outcomes of statin use in ESRD patients on HD with documented dyslipidemia over a two-year period from 1 January 2018 to 30 December 2019. The primary endpoints evaluated the clinical outcomes of statins by assessing changes in specific lipid parameters, including low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-C). The secondary endpoints assessed safety by monitoring liver enzymes and creatine kinase (CK) levels. <b>Results</b>: Among 179 participants, diabetes mellitus was present in 134 patients (74.9%), while 168 patients (93.9%) had hypertension. Cardiovascular events occurred in 95 patients (53.1%). Statin therapy was administered to 146 patients (82.0%), with atorvastatin being the most frequently prescribed statin (69.3%). Modest reductions in LDL-C levels were observed in the rosuvastatin and atorvastatin groups, whereas slight increases were noted in the simvastatin and non-statin groups. None of these within-group changes were statistically significant. In the atorvastatin group, LDL-C decreased slightly from 2.058 to 2.003 mmol/L. The rosuvastatin group experienced a more pronounced LDL-C reduction from 2.607 to 2.113 mmol/L. Conversely, the simvastatin group showed an LDL-C increase from 1.550 to 1.901 mmol/L. Among the non-statin group, LDL-C increased from 2.678 to 2.820 mmol/L. Liver enzyme and CK levels fluctuated slightly but remained within normal ranges. <b>Conclusions</b>: This study evaluated statin therapy in hemodialysis patients with dyslipidemia. Although modest reductions in LDL-C levels were observed in the atorvastatin and rosuvastatin groups, statin therapy did not reduce the incidence of atherosclerotic events in hemodialysis patients with dyslipidemia. Additionally, statin use was not associated with any clinically or statistically significant effects.https://www.mdpi.com/1424-8247/18/6/911end-stage renal diseaseshemodialysisstatinsdyslipidemiaefficacysafety |
| spellingShingle | Abdulmalik S. Alotaibi Mohamed A. Albekery Ahmed A. Alanazi Ibrahim S. Alhomoud Khalid A. Alamer Mohammad Shawaqfeh Reem H. Alshammari Fayez Alhejaili Muthana Al Sahlawi Ibrahim Aldossary Hajar Adel Aljuayl Mohammad Alkathiri Shmeylan Alharbi Abdulkareem Albekairy Abdulmalik Alkatheri Evaluation of Statins Use in Hemodialysis Patients: A Retrospective Analysis of Clinical and Safety Outcomes Pharmaceuticals end-stage renal diseases hemodialysis statins dyslipidemia efficacy safety |
| title | Evaluation of Statins Use in Hemodialysis Patients: A Retrospective Analysis of Clinical and Safety Outcomes |
| title_full | Evaluation of Statins Use in Hemodialysis Patients: A Retrospective Analysis of Clinical and Safety Outcomes |
| title_fullStr | Evaluation of Statins Use in Hemodialysis Patients: A Retrospective Analysis of Clinical and Safety Outcomes |
| title_full_unstemmed | Evaluation of Statins Use in Hemodialysis Patients: A Retrospective Analysis of Clinical and Safety Outcomes |
| title_short | Evaluation of Statins Use in Hemodialysis Patients: A Retrospective Analysis of Clinical and Safety Outcomes |
| title_sort | evaluation of statins use in hemodialysis patients a retrospective analysis of clinical and safety outcomes |
| topic | end-stage renal diseases hemodialysis statins dyslipidemia efficacy safety |
| url | https://www.mdpi.com/1424-8247/18/6/911 |
| work_keys_str_mv | AT abdulmaliksalotaibi evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT mohamedaalbekery evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT ahmedaalanazi evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT ibrahimsalhomoud evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT khalidaalamer evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT mohammadshawaqfeh evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT reemhalshammari evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT fayezalhejaili evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT muthanaalsahlawi evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT ibrahimaldossary evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT hajaradelaljuayl evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT mohammadalkathiri evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT shmeylanalharbi evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT abdulkareemalbekairy evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes AT abdulmalikalkatheri evaluationofstatinsuseinhemodialysispatientsaretrospectiveanalysisofclinicalandsafetyoutcomes |